The polyanionic aromatic suramin is a classical trypanocidal drug, and whilst first introduced in 1922, remains an important first line therapeutic for African sleeping sickness. Suramin contains two symmetrical polysulphonated napthylamine groups giving rise to six negative charges at physiological pH, preventing passive diffusion across biological membranes. Hence, specific uptake mechanisms into the parasite must exist and a complex mode of action such as interference with the import of newly synthesised glycolytic enzymes into glycosomes has been proposed to underpin the antiparasitic action of suramin [1 /4]. Suramin may also bind to nascent cytosolic glycolytic enzymes and prevent glycosomal import [5]. However, an unequivocal description of how suramin enters the trypanosome and exhibits its toxicity remains to be presented. Interest in suramin has grown recently with its new use as an antitumour agent. Coppens et al. described evidence for receptormediated endocytosis of host low density lipoprotein (LDL) in both bloodstream (BSF) and procyclic (PCF) stages [6 /8] and proposed an LDL-receptor cycle similar to that in metazoans [7]. Vansterkenburg et al. [9] suggested entry of suramin via the LDL-receptor based on several observations. Firstly, suramin binds with considerable affinity to both human LDL and serum albumin in vitro and suramin uptake into trypanosomes requires pre-binding to LDL, suggesting a carrier function for the lipoprotein. Secondly, addition of more LDL to the incubation medium increases suramin accumulation, but conversely, addition of serum albumin decreases suramin uptake, suggesting partitioning between these plasma components. Thirdly, preincubation of suramin with albumin alone abrogates drug uptake, consistent with accumulation of the drug via a trypanosomal LDL-receptor and not fluid phase endocytosis, the route of entry for serum albumin [6]. Finally, suramin interferes with LDL-binding and uptake into live Trypanosoma brucei in a concentration-dependent manner, suggesting competition for the LDL-binding site on the LDL-receptor [9]. As the trypanosomal LDL-receptor gene has not been cloned, direct genetic evidence characterising the role of this receptor in suramin uptake is not available. Several important proteins involved in endocytosis have been described recently, including members of the trypanosome Rab family [10,11]. Rab proteins are small GTPases, which control a number of central aspects of vesicle transport; in endocytosis Rab5 and Rab4 are responsible for the transport of cargo through early endosomes and recycling endosomes, respectively. These two processes are clearly closely coupled, but distinct as unique protein effectors interact with Rab4 and Rab5, and mutations in these proteins have specific effects on endocytosis [12]. Most importantly, the membranous compartments to which trypanosomal Rab4 and Rab5 (TbRAB4 and TbRAB5) localise are overlapping, but nonidentical [10]. Recently, we have demonstrated that the functions of the two TbRAB5 isoforms (termed A and B) are distinct, with TbRAB5A having a clear role in transport of GPI-anchored proteins and LDL, and TbRAB5B being involved in transmembrane protein endocytosis [11]. Creation of point mutations in Rab proteins to prevent GTP hydrolysis (Q0/L substitution) locks the protein in the GTP-bound state (effectively active); such a strategy, pioneered in higher eukaryotes, Abbreviations: BSA, bovine serum albumin; BSF, bloodstream form; LDL, low density lipoprotein; PCF, procyclic culture form. * Corresponding author. Tel.: /44-20-7594-5277 E-mail address: mfield@ic.ac.uk (M.C. Field). 1 These authors contributed equally to this work. Molecular & Biochemical Parasitology 122 (2002) 217 /221
Read full abstract